Fennec Pharmaceuticals Inc, a specialty pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for the company’s unique formulation of sodium thiosulfate (STS) called Pedmark for the prevention of platinum-induced ototoxicity in pediatric patients one month to 18 years of age with localized, non-metastatic, solid tumors. Pedmark had previously received both Breakthrough Therapy and Fast Track Designation by the FDA in March 2018.
Matthew Allsop is the Video Content Manager at Hearingtracker.com. He practices from his London-based practice, Harley Street Hearing. You can get in touch on email@example.com regarding new content ideas or to become a patient.
#hearing #hearingloss #hearingaids